Recursion Pharmaceuticals (NASDAQ:RXRX) Downgraded by Wall Street Zen to Sell

Recursion Pharmaceuticals (NASDAQ:RXRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

RXRX has been the subject of a number of other research reports. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Finally, Bank of America dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Down 6.7%

NASDAQ RXRX opened at $2.94 on Friday. Recursion Pharmaceuticals has a 12 month low of $2.91 and a 12 month high of $7.18. The company has a market capitalization of $1.55 billion, a P/E ratio of -1.99 and a beta of 0.97. The company’s 50 day simple moving average is $3.74 and its 200 day simple moving average is $4.48. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The firm’s revenue for the quarter was up 671.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.53) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 21,383 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.18, for a total transaction of $89,380.94. Following the transaction, the chief financial officer directly owned 761,550 shares in the company, valued at approximately $3,183,279. The trade was a 2.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 220,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total transaction of $924,000.00. Following the sale, the director directly owned 6,429,863 shares in the company, valued at approximately $27,005,424.60. This trade represents a 3.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 511,063 shares of company stock valued at $2,135,702. Company insiders own 8.43% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RXRX. Xponance Inc. lifted its stake in Recursion Pharmaceuticals by 8.0% in the 3rd quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after acquiring an additional 2,221 shares in the last quarter. NewEdge Advisors LLC boosted its position in Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after acquiring an additional 2,428 shares during the period. Equitable Holdings Inc. grew its stake in Recursion Pharmaceuticals by 7.1% during the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after acquiring an additional 2,600 shares in the last quarter. Cherry Creek Investment Advisors Inc. grew its stake in Recursion Pharmaceuticals by 4.1% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company’s stock valued at $326,000 after acquiring an additional 2,649 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Recursion Pharmaceuticals by 1.2% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock valued at $954,000 after purchasing an additional 2,753 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.